Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Diamond Headache Clinic
ClinicalTrials.gov Identifier:
NCT00471952
First received: May 8, 2007
Last updated: April 24, 2012
Last verified: April 2012

May 8, 2007
April 24, 2012
April 2007
February 2008   (final data collection date for primary outcome measure)
The comparative percentage of migraine attacks that produce pain free response at 2 hours in the Maxalt 10mg MLT plus caffeine 75mg arm versus the Maxalt 10mg MLT plus placebo caffeine versus double placebo. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
The comparative percentage of migraine attacks that produce pain free response at 2 hours in the Maxalt 10mg MLT plus caffeine 75mg arm versus the Maxalt 10mg MLT plus placebo caffeine versus double placebo. [ Time Frame: 2 hours ]
Complete list of historical versions of study NCT00471952 on ClinicalTrials.gov Archive Site
  • The comparative percentage of attacks that produce pain relief at 2 hours. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
  • The comparative percentage of attacks that produce a pain free response and do not require re-treatment during the subsequent 24 hours and are not associated with headache pain recurrence. [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • The comparative percentage of resolution of associated symptoms of migraine present at the time of treatment as well as achieving a pain free response within 2 hours with each of the treatments. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
  • The comparative number of patients reporting adverse effects to study medication, the type of adverse events reported and the percentage of attacks that are associated with the adverse effect. [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
  • Patient global evaluation for each of the treatments [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • The comparative percentage of attacks that produce pain relief at 2 hours. [ Time Frame: 2 hours ]
  • The comparative percentage of attacks that produce a pain free response and do not require re-treatment during the subsequent 24 hours and are not associated with headache pain recurrence. [ Time Frame: 24 hours ]
  • The comparative percentage of resolution of associated symptoms of migraine present at the time of treatment as well as achieving a pain free response within 2 hours with each of the treatments. [ Time Frame: 2 hours ]
  • The comparative number of patients reporting adverse effects to study medication, the type of adverse events reported and the percentage of attacks that are associated with the adverse effect. [ Time Frame: 24 hours ]
  • Patient global evaluation for each of the treatments [ Time Frame: 24 hours ]
Not Provided
Not Provided
 
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine.

Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar).

One headache will be treated with a combination of Maxalt 10mg MLT and caffeine.

Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo.

A third headache will be treated with just placebo.

Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.

Oral Maxalt has an extensive record of providing relief of acute migraine headache with 2 hours in the vast majority of patients, especially when undertaken as an early intervention strategy. Caffeine has been demonstrated to have analgesic effects in patients treating tension type headache and is found as part of a combination including aspirin and acetaminophen as a treatment for acute migraine headache.

The mechanism by which Maxalt relieves migraine headache is believed to be through action on 5HT1B/1D receptors both on blood vessels as well as centrally. Caffeine may have effects on relief of migraine through modifying norepinephrine related mechanisms which have been suggested through clinical research. Patients commonly report that they may obtain partial or complete relief of their migraines by consuming the modest amounts of caffeine found in a cup of coffee. this is estimated to be approximately 100mg per cup. The analgesic effects of caffeine appear to be most significant in the first 3 hours after ingestion. Recent work suggests that intervention in migraine when the pain is still mild and has not persisted for a prolonged duration may increase the likelihood of complete migraine response. Therefore, the combination of the two agents with activity in migraine that work early in the migraine process, have good tolerability at the proposed doses and working via different mechanism may increase the likelihood of patients achieving better response with their migraine treatment than that which is currently available.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
  • Migraine With Aura
  • Migraine Without Aura
  • Drug: Maxalt 10mg MLT plus Caffeine 75mg
    One migraine attack will be treated
  • Drug: Maxalt 10mg MLT plus Placebo
    One migraine attack will be treated with Maxalt 10mg plus placebo
  • Drug: Placebo + Placebo
    One migraine attack will be treated with double placebo
  • Experimental: 1
    Maxalt 10mg with Caffeine 75mg
    Intervention: Drug: Maxalt 10mg MLT plus Caffeine 75mg
  • Active Comparator: 2
    Maxalt 10mg plus Placebo
    Intervention: Drug: Maxalt 10mg MLT plus Placebo
  • Placebo Comparator: 3
    Double placebo
    Intervention: Drug: Placebo + Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
April 2008
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is 18-65 years of age
  • Diagnosis of migraine with or without aura
  • 1 year history of migraine with 1-6 migraine attacks per month in the the three months prior to screening
  • Medication for migraine prevention with a stable dose for at least 1 month prior to screening
  • Has successfully treated a migraine attack with a triptan medication

Exclusion Criteria:

  • Confirmed or suspected ischemic heart disease
  • History of congenital heart disease
  • History of cerebrovascular disease, including stroke
  • History of ischemic abdominal disease
  • Uncontrolled hypertension
  • History of epilepsy
  • History of basilar or hemiplegic migraine
  • Impaired hepatic or renal function
  • Greater than 15 headache days per month
  • Subjects on an MAOI
  • Subjects taking and ergotamine, or ergot containing preventive medication
  • Subject is pregnant, trying to become pregnant or breast feeing
  • Evidence of alcohol or substance abuse in the last year
  • History of caffeine withdrawal headache
  • Consumes more than 275 mg of caffeine on daily basis from dietary and medication sources
  • Taking propanolol
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00471952
DHC 09
No
Diamond Headache Clinic
Diamond Headache Clinic
Merck Sharp & Dohme Corp.
Principal Investigator: Frederick G Freitag, DO Diamond Headache Clinic
Diamond Headache Clinic
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP